RENE GONZALEZ to Drug Resistance, Neoplasm
This is a "connection" page, showing publications RENE GONZALEZ has written about Drug Resistance, Neoplasm.
Connection Strength
0.451
-
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017 11; 86:37-45.
Score: 0.104
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18.
Score: 0.088
-
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74.
Score: 0.076
-
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 2012 Oct; 132(10):2440-2450.
Score: 0.071
-
Novel therapies in melanoma. Immunotherapy. 2011 Dec; 3(12):1461-9.
Score: 0.069
-
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96.
Score: 0.022
-
A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma. Cancer Med. 2015 May; 4(5):643-50.
Score: 0.021